Icon (ICLR)

• Market cap: $13.3B
• 1 day: -2.59%
• 5 days: -0.36%
• 1 month: -3.06%
• 3 months: 15.93%
• 6 months: -8.24%
• Year to date: -19.83%
• 1 year: -42.33%
• 5 years: -9.51%
• 10 years: 117.9%
• Sector: Healthcare
• Industry: Diagnostics & Research

About: Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.

Employees: 39,900

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

103% more call options, than puts

Call options by funds: $18.1M | Put options by funds: $8.93M

2.38% more ownership

Funds ownership: 91.65% [Q1] → 94.03% (+2.38%) [Q2]

8% less funds holding in top 10

Funds holding in top 10: 12 [Q1] → 11 (-1) [Q2]

12% less funds holding

Funds holding: 549 [Q1] → 482 (-67) [Q2]

16% less capital invested

Capital invested by funds: $13.1B [Q1] → $11B (-$2.06B) [Q2]

28% less repeat investments, than reductions

Existing positions increased: 148 | Existing positions reduced: 205

45% less first-time investments, than exits

New positions opened: 72 | Existing positions closed: 132

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $175
• Avg. target: $217
• High target: $240

9 analyst ratings

• positive: 6 67%
• neutral: 3 33%
• negative: 0 0%

Jefferies David Windley	$175	Hold Downgraded	9 Sep 2025
Rothschild & Co Jamie Clark	$236	Buy Upgraded	3 Sep 2025
Baird Eric Coldwell	$224	Outperform Maintained	2 Sep 2025
Citigroup Patrick Donnelly	$200	Neutral Downgraded	21 Aug 2025
Mizuho Ann Hynes	$225	Outperform Maintained	25 Jul 2025